Consolidating the Digital Slide: How Agilent's $270M Proscia Acquisition Signals the End of Standalone Pathology AI
Dr. Dereck Mush, MD, MBA
PathAI
AI-powered pathology solutions designed to improve diagnostic accuracy and drug development.
What they do
The company provides machine learning tools to assist pathologists in diagnosing diseases like cancer. It partners with biopharmaceutical companies to evaluate drug efficacy in clinical trials and sells diagnostics tools to reference laboratories.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Digital pathology software
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Boston, USA
- Region
- North America
- Founded
- 2016
- Total funding
- $255M raised
Notable investors: General Catalyst, Tiger Global Management, D1 Capital Partners, General Atlantic.
Also in Imaging & Diagnostics
Related on The Signal
Dr. Dereck Mush, MD, MBA
The AI-Native Practice Playbook: Why Epsilon Health Built a Medical Group Instead of Selling Software
Dr. Dereck Mush, MD, MBA
Digital Pathology Finally Has FDA-Cleared AI. Why Hospital Adoption Is Still Spotty
Dr. Dereck Mush, MD, MBA
Mobile Clinics Lean on Scheduling Software to Reach the Patients Who Need Them Most
Dr. Dereck Mush, MD, MBA